Work

Research progress on tofacitinib in the treatment of chronic actinic dermatitis

Year: 2024

Type: article

Abstract: Chronic actinic dermatitis (CAD) is a group of immune-mediated diseases characterized by photosensitivity. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, is currently the most extensively reported and widely used JAK inhibitor for the treatment of CAD. This article aims to briefly overview the background of CAD and tofacitinib, as well as to summarize the mechanisms of tofacitinib in the treatment of chronic actinic dermatitis, commonly used therapeutic dosages, specific efficacy, and adverse effects. Additionally, a brief comparison of tofacitinib with other JAK inhibitors is also included.

Source: DOAJ (DOAJ: Directory of Open Access Journals)

DOI: 10.3969/j.issn.1674-8468.2024.12.012

Authors: WU Hui, SHEN Haojia, HE Zezhi, CHEN Jiaoquan, LI Runxiang, ZHU Huilan

Institutions: Guangzhou Institute of Dermatology, Guangzhou Medical University

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6966895291

FWCI:

Cites:

Cited by:

Related to: